NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Akorn, Inc. (NASDAQ: AKRX)
Class Period: August 1, 2018 - January 8, 2019
Deadline: April 22, 2019
For more info: www.bgandg.com/akrx

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Akorn’s management misled investors concerning the severity of Akorn’s manufacturing violations at its Decatur, Illinois facility; (2) Akorn’s responses to the Food and Drug Administration’s (“FDA”) Form 483—which contained a list of observations made by the FDA during its inspection of Akorn’s Decatur, Illinois facility in April and May 2018—would be deemed inadequate by the FDA; (3) Akorn repeatedly failed to correct manufacturing violations at this facility; (4) the foregoing would subject Akorn to heightened regulatory scrutiny by the FDA; and (5) as a result, Akorn’s public statements were materially false and misleading at all relevant times.

Amarin Corporation (NASDAQ: AMRN)
Class Period: September 24, 2018 - November 8, 2018
Deadline: April 23, 2019
For more info: www.bgandg.com/amrn

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

Conagra Brands, Inc. (NYSE: CAG)
Class Period: June 27, 2018 - December 19, 2018, and/or purchased shares of Conagra’s common stock pursuant and/or traceable to Conagra’s secondary public offering commenced on or about October 9, 2018 (“SPO”)
Deadline: April 23, 2019
For more info: www.bgandg.com/cag

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that material information about Conagra’s acquisition of Pinnacle Foods, Inc. (“Pinnacle”), including that: (1) Conagra inadequately performed proper due diligence in connection with the acquisition of Pinnacle; (2) the performance of Pinnacle’s three leading brands was not deteriorating due to intensified competition, but to self-inflicted subpar innovation and executional missteps; (3) Pinnacle’s business was performing so poorly that it had resorted to pushing promotional deals to retailers in an effort to boost sales; and (4) consequently, Defendant’s public statements were materially false and/or misleading and/or lacked a reasonable basis when made.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.